The generic name for Trelegy is fluticasone furoate-umeclidinium-vilanterol [1]. Trelegy is a combination inhaler used for the maintenance treatment of asthma or chronic obstructive pulmonary disease (COPD) [1]. It contains three active ingredients: fluticasone furoate, an inhaled corticosteroid; umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist [2].
What conditions does Trelegy treat?
Trelegy is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD [1]. It is also approved for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled on a combination of an inhaled corticosteroid and a long-acting beta2-agonist, or who are already treated with fluticasone furoate and vilanterol [1].
How does Trelegy work?
Fluticasone furoate helps reduce inflammation in the airways. Umeclidinium works by relaxing the muscles around the airways, making it easier to breathe. Vilanterol also helps to relax airway muscles by acting on beta2-adrenergic receptors [2]. Together, these three medications work to improve breathing for individuals with COPD and certain types of asthma.
When does Trelegy's patent protection end?
Patent information for medications like Trelegy is complex and can involve multiple patents covering the drug substance, formulations, and methods of use. According to DrugPatentWatch.com, specific patent expiry dates for Trelegy's components and its combination formulation can vary. Information on the patent status and exclusivity periods for fluticasone furoate-umeclidinium-vilanterol can be found on DrugPatentWatch.com [3].
What are the potential side effects of Trelegy?
Common side effects of Trelegy can include upper respiratory tract infections, pneumonia, bronchitis, sore throat, hoarseness, and oral thrush [1]. Patients should consult with their healthcare provider about potential risks and side effects.
Can generic versions of Trelegy be developed?
Generic versions of combination inhalers like Trelegy can be challenging to develop and gain approval. The U.S. Food and Drug Administration (FDA) has specific requirements for demonstrating the bioequivalence and therapeutic equivalence of generic combination drugs. The development and approval process for a generic can occur after the expiration of relevant patents and market exclusivity [3].
How does Trelegy compare to other COPD or asthma medications?
Trelegy is a triple therapy combining an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-agonist. Other treatment options for COPD and asthma include monotherapies or dual bronchodilator therapies, which combine two types of bronchodilators (LABA and LAMA) [1]. The choice of medication depends on the severity of the disease, individual patient response, and treatment history.
What is the typical cost of Trelegy?
The cost of Trelegy can vary significantly depending on insurance coverage, pharmacy, and geographic location. Patients often utilize savings cards or patient assistance programs offered by the manufacturer to help manage out-of-pocket expenses.
What are the risks associated with Trelegy?
Potential risks include an increased risk of pneumonia in patients with COPD, paradoxical bronchospasm, and certain cardiovascular effects. It is important for patients to discuss their full medical history with their doctor to determine if Trelegy is an appropriate treatment option [1].
Who manufactures Trelegy?
Trelegy is manufactured by GlaxoSmithKline (GSK) [1].
What are the active ingredients in Trelegy?
The active ingredients in Trelegy are fluticasone furoate, umeclidinium, and vilanterol [2].
What happens if I miss a dose of Trelegy?
If a dose of Trelegy is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Patients should not take a double dose to make up for a missed one [1].
Sources:
1. https://www.trelegy.com/
2. https://www.drugpatentwatch.com/drugs/trelegy-elliptic/
3. https://www.drugpatentwatch.com/